J.M. Hartwell’s Teva Pharmaceuticals TEVA Stock Holding History

J.M. Hartwell’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-9,090	Closed	-$330K	–	90
2016 Q4	$330K	Sell	9,090 -1,300	-13%	-$51.9K	0.08%	71
2016 Q3	$478K	Hold	10,390	–	–	0.11%	58
2016 Q2	$522K	Hold	10,390	–	–	0.13%	53
2016 Q1	$556K	Hold	10,390	–	–	0.13%	52
2015 Q4	$682K	Hold	10,390	–	–	0.16%	45
2015 Q3	$587K	Hold	10,390	–	–	0.13%	50
2015 Q2	$614K	Sell	10,390 -800	-7%	-$49.4K	0.13%	56
2015 Q1	$697K	Buy	11,190 +200	+2%	+$11.6K	0.15%	44
2014 Q4	$632K	Hold	10,990	–	–	0.15%	48
2014 Q3	$591K	Hold	10,990	–	–	0.14%	54
2014 Q2	$576K	Buy	10,990 +300	+3%	+$15.3K	0.12%	60
2014 Q1	$565K	Buy	10,690 +1,600	+18%	+$73.9K	0.12%	57
2013 Q4	$364K	Hold	9,090	–	–	0.07%	80
2013 Q3	$343K	Hold	9,090	–	–	0.08%	83
2013 Q2	$356K	Buy	+9,090	New	+$354K	0.09%	72

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

J.M. Hartwell's TEVA Position: Q1 2017 in Review

J.M. Hartwell sold out of Teva Pharmaceuticals (TEVA) in Q1 2017, closing a stake of 9,090 shares — an estimated $330K sold.

J.M. Hartwell first reported a position in TEVA in Q2 2013 and held it in 15 quarters. The position peaked at $697K in Q1 2015. 686 funds tracked by Wall St. Rank hold TEVA as of Q1 2017.

J.M. Hartwell reported no remaining Teva Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
J.M. Hartwell sold 9,090 Teva Pharmaceuticals shares in Q1 2017, an estimated $330K.
J.M. Hartwell first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 15 quarters.
J.M. Hartwell's Teva Pharmaceuticals position peaked at $697K in Q1 2015.
686 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2017.

Based on J.M. Hartwell's 13F filing for Q1 2017, filed 18 Apr 2017.